(Source: H Lundbeck A/S) The head-to-head QUALIFY study compared the effectiveness of aripiprazole once-monthly to paliperidone palmitate once-monthly in adult patients with schizophrenia Patients treated with aripiprazole once-monthly demonstrated a statistically significant improvement on the primary endpoint, quality-of-life measure, compared to those treated with paliperidone palmitate Discontinuations due to adverse events occurred in 10.8% of patients in the aripiprazole once-monthly group compared to 18.4% of patients in the paliperidone once-monthly group Valby, Denmark and Princeton, N.J., U.S., 3 November 2014 - H. Lundbeck A/S (Lundbeck) and Otsuka America Pharmaceutical Inc....
↧